Gilead Sciences stock trades 0.53 percent below EUR 140.02
Published on 10/24/2026 at 10:38 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWSWeekend trading and company news
- On October 22, 2026, Gilead agreed to acquire PepStarâs HCXT-2001 program for $1.275 billion upfront.
- Gilead Sciences stock trades at EUR 139.28 at 10:36 a.m. CEST on October 24, 2026, 0.53 percent below the Xetra close of October 23, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Gilead Sciences stock trades in weekend trading at Lang & Schwarz at EUR 139.28 at 10:36 a.m. CEST on October 24, 2026, 0.53 percent below the Xetra close of EUR 140.02 on October 23, 2026. On October 22, 2026, Gilead Sciences announced an agreement to acquire PepStar Therapeuticsâ oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion in upfront cash consideration, according to the Gilead Sciences release.
Market context: Market report S&P 500.
The week in figures
The Lang & Schwarz weekend price is EUR 139.28. It is EUR 0.74 below the Xetra close of EUR 140.02 on October 23, 2026, a difference of minus 0.53 percent. Xetra is closed on October 24, 2026.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Chronology of the week
On October 22, 2026, Gilead Sciences announced the definitive agreement with PepStar Therapeutics. The program includes HCXT-2001, an investigational oral macrocyclic peptide inhibitor of IL-23R currently in Phase 1 clinical trials. The transaction gives Gilead worldwide rights to the program and is expected to close in the fourth quarter of 2026, subject to customary conditions, according to the company announcement.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. Gileadâs announcement also states that the PepStar transaction is expected to close in the fourth quarter of 2026, subject to customary conditions.
